Project Grant HT94252510821
- The Defense Health Agency awarded a $487,765 Project Grant to The Johns Hopkins University under the Military Medical Research and Development program (CFDA 12.420) to develop "A NOVEL DIGITAL TWIN FOR OPTIMIZING NORMOTHERMIC VCA PRESERVATION". This 3-year research project, with a period of performance from September 30, 2025 to September 29, 2028, aims to advance biomedical research and innovation in healthcare solutions for military service members and the public. The Military...
- The University of Pittsburgh was awarded a $499,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research to develop nontoxic immunosuppression therapies using Vitamin D3 analogues for vascularized composite allotransplantation (VCA). The grant period runs from September 1, 2024 to August 31, 2026. This research aims to transform healthcare for military service members,...
- The U.S. Department of Defense's Defense Health Agency (DHA) awarded a $750,000 Project Grant to Stanford University to implement a spatial and single-cell multiplexed platform for the development of targeted therapies for vascularized composite allotransplantation. The funding is provided through the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports advanced biomedical research to transform healthcare for military service members and the broader...
- The Department of Defense's Defense Health Agency awarded Carnegie Mellon University a $258,606 Project Grant on January 1, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports research on "Targeted Deep Brain Minimally-Invasive Neurostimulation," with a completion date of December 31, 2025. As part of this effort, Carnegie Mellon is collaborating with Allegheny-Singer Research Institute, which has received a $xxx,xxx sub-grant to conduct...
- This $700,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the "RESUSCITATION BY ENDOTHELIAL STABILIZATION AND TARGETED OXYGEN RESCUE (RESTOR) PLATFORM FOR VASCULARIZED COMPOSITE ALLOTRANSPLANTATION" research initiative at Duquesne University. The project aims to transform healthcare for military service members and the broader public through innovative biomedical research focused on improving...
- The Defense Health Agency awarded a $899,999 Project Grant to Wake Forest University Health Sciences under the Military Medical Research and Development program (CFDA 12.420) to develop a novel point-of-care assay for monitoring rejection and immunosuppression in vascularized composite allotransplantation (VCA) recipients. The project aims to transform healthcare for service members and the public through innovative biomedical research focused on medical solutions for the battlefield. The...
- The U.S. Defense Health Agency has awarded a $499,998 Project Grant to the University of Colorado-Denver under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from November 1, 2024 to October 31, 2026, is for developing a preservation method for vascularized composite allotransplantation (VCA) during static cold storage. This research aims to transform healthcare for military service members and the broader public by...
- The Defense Health Agency awarded a $499,998.00 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "Identifying Biomarkers of Human VCA Rejection to Enable Noninvasive Diagnostic Testing." This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The research project at Brigham &...
- The Department of the Army Medical Command awarded a $750,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Leland Stanford Junior University. The grant, which runs from September 1, 2024 to August 31, 2027, will fund the implementation of a spatial and single-cell multiplexed platform for the development of targeted therapies for vascularized composite allotransplantation. This research, to be conducted at Stanford University, aims to transform...
- This Project Grant award of $113,340 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports ex vivo preservation research for vascularized composite allotransplantation (VCA) at Cedars-Sinai Medical Center in West Hollywood, CA. The goal is to make tolerance induction protocols clinically applicable for VCA. The award period runs from August 15, 2025 to August 14, 2028. As a leading research institution, Cedars-Sinai Medical Center specializes...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $383,029 to Carnegie Mellon University to develop a novel digital twin for optimizing normothermic vascularized composite allotransplantation (VCA) preservation. The award period runs from September 30, 2025 to September 29, 2028. Carnegie Mellon University, through its Office of Sponsored Programs, will leverage its expertise in advanced technologies, scientific disciplines, and interdisciplinary research to create this digital twin solution, which aims to transform healthcare for military service members, veterans, and the broader public by advancing medical research and developing innovative medical solutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $383.0k | 7/30/25 |